- So far in 2021, Mind Cure has embarked on an aggressive plan to strengthen its advisory board and file for new provisional patents for its fully synthetic ibogaine
- In January, the company also announced an amended agreement to grow the size of an earlier-announced bought deal financing
- This year has also seen the launch of the second stage of manufacturing of Ibogaine for use in psychedelic clinical research
- Mind Cure also continues to strengthen its proprietary digital therapeutics technology (“DTx”), iSTRYM
- All of Mind Cure’s decisions thus far are designed to help the company achieve overall growth and fulfill its vision of easing suffering, increasing productivity, and enhancing mental health
Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) is regarded as a diversified life sciences company that is at the forefront of the mental health industry. The company’s current focus is on developing digital therapeutics, researching psychedelic compounds, and innovating and commercializing new ways to improve and promote healing for individuals dealing with mental health challenges.
In a move to grow its market presence and overall brand equity, Mind Cure has embarked on an aggressive plan, firstly with strengthening its advisory board and filing for new provisional patents for its fully synthetic line of products.
So far, in 2021, the company has expanded its product line with the launch of the second stage manufacturing of Ibogaine (https://ibn.fm/9LNQF). Ibogaine is a psychoactive substance present naturally in the roots of the African iboga tree. The company is researching the substance’s potential to treat traumatic brain injury (“TBI”).
In January 2021, Mind Cure ushered the new year by announcing an amended agreement with a syndicate of underwriters to grow the size of an earlier-announced bought deal financing. This was a big move for the company that saw a growth in its valuation, with the proceeds from the offering used to further its agenda for product research, development, and expansion (https://ibn.fm/QQM4Y).
In August, Mind Cure announced the appointment of Jerry White into the company’s advisory board (https://ibn.fm/STdMZ). For an individual recognized globally for his efforts in engaging large audiences to power global movements and a co-recipient of the 1997 Nobel Peace Prize, this was a big move for Mind Cure. More so, the company projected that with Mr. White’s addition to the board, it would be well-positioned to achieve bigger and better goals, all while working towards its overall vision of building mental wealth globally.
Mind Cure also continues to strengthen its proprietary technology. Its artificial intelligence (“AI”) driven software platform, iSTRYM, is set to enable personalized and quantified outcomes in psychedelic-assisted therapy, with the company projecting a minimal viable product (“MVP”) of the software by the third quarter (“Q3”) of the 2021 fiscal year. Digital therapeutics (“DTx”) continue to leverage smart devices to induce behavioral changes among patients (https://ibn.fm/oJfPw).
2021 has, so far, been good for Mind Cure. The company continues to push the envelope in research, technology, management, and overall approach towards the mental health market. Everything that the company has done so far is geared towards achieving overall growth and fulfilling its vision of easing suffering, increasing productivity, and enhancing mental health. As such, the company is very optimistic about the future.
For more information, visit the company’s website at www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
